Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of vebreltinib + PLB1004 vs osimertinib in first-line EGFR-mutant, MET-abnormal NSCLC
ChiCTR2600127991Phase 2Completed
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jul 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Test group: vebreltinib + PLB1004 with Control group: osimertinib (2 arms). Primary endpoint: Objective Response Rate (ORR). Started Jul 2026; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600127991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127991.